New AMPK Drug Boosts Metabolism and Cuts Liver Fat in Prediabetes Trial
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
Summary
A new drug called ATX-304, developed by Cambrian Bio, showed promising early results in adults with obesity and prediabetes. In an 8-week randomized controlled trial, the drug boosted resting metabolic rate by 8%, significantly lowered triglycerides and liver fat, and reduced visceral belly fat — all without serious side effects. It works by activating the AMPK pathway, a cellular energy sensor linked to improved glucose uptake and mitochondrial function. Adiponectin, a hormone associated with better insulin sensitivity, also increased significantly. The drug appears to improve multiple metabolic markers simultaneously, which is notable for a single compound. Larger Phase 2 trials are planned to test higher doses for muscle function and weight loss.
Detailed Summary
Cambrian Bio has released early human trial results for ATX-304, a novel drug targeting prediabetes and metabolic dysfunction through a mechanism called AMPK Network Activation. Presented at the American Diabetes Association's 86th Scientific Sessions in June 2026, the data suggest the compound can meaningfully shift multiple metabolic markers in just eight weeks — a finding with broad implications for longevity-focused medicine.
The Phase 1b trial enrolled 23 adults with obesity and prediabetes in a randomized, double-blind, placebo-controlled design. Participants took 400 mg of ATX-304 daily for eight weeks. Results showed statistically significant improvements across several key biomarkers: plasma adiponectin rose, triglycerides fell, liver fat decreased as measured by MRI, and visceral adipose tissue was reduced. Resting metabolic rate increased by 8%, a meaningful shift given that metabolic slowdown is a hallmark of aging and obesity.
The drug's mechanism centers on activating AMPK, an energy-sensing enzyme that regulates glucose uptake and mitochondrial respiration. Crucially, a companion study showed AMPK activation occurred without depleting cellular ATP, suggesting the energy-sensing pathway is being optimized rather than stressed. This matters because prior concerns about mitochondrial safety have limited similar compounds.
Safety data were reassuring. Adverse events were mild and comparable to placebo, with no signs of mitochondrial failure, no elevation in core body temperature, and no increase in 24-hour heart rate — metrics that would signal metabolic overstimulation.
Caveats remain significant. This was a small 23-person trial designed primarily to assess safety and early signals, not to prove efficacy. Weight loss was minimal at this dose. Two larger Phase 2 trials, REWIRE-1 and REWIRE-2, will test higher exposures and target muscle function and weight loss outcomes. Until those results emerge, ATX-304 remains an intriguing but unproven candidate.
Key Findings
- ATX-304 increased resting metabolic rate by 8% in adults with obesity and prediabetes after 8 weeks
- Liver fat (MRI-measured) and visceral adipose tissue both decreased significantly compared to placebo
- Triglycerides fell and adiponectin rose significantly, indicating improved metabolic and insulin health
- AMPK was activated without depleting cellular ATP, suggesting a safe mitochondrial energy profile
- Adverse events were mild and placebo-comparable, with no signs of mitochondrial stress or overheating
Methodology
This is a news report summarizing Phase 1b clinical trial data presented at a major scientific conference. The trial was randomized, double-blind, and placebo-controlled, lending meaningful credibility, though the sample size of 23 participants limits statistical power and generalizability. Results have not yet been published in a peer-reviewed journal.
Study Limitations
The trial enrolled only 23 participants, making it underpowered to confirm efficacy or detect rare adverse events. Results were presented at a conference and have not been peer-reviewed or published in full. The minimal weight loss at this dose level suggests higher doses in Phase 2 may introduce new safety considerations that are not yet characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.